Utah Medical Products Return on Equity (ROE) Growth & History (UTMD)
Utah Medical Products's return on equity was 9.54% for fiscal 2025.
View full Utah Medical Products company overviewUtah Medical Products annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 9.54% | −1.76 pp |
| 2024 | 2024-12-31 | 11.29% | −2.42 pp |
| 2023 | 2023-12-31 | 13.72% | −1.17 pp |
| 2022 | 2022-12-31 | 14.88% | +0.79 pp |
| 2021 | 2021-12-31 | 14.09% | +3.50 pp |
| 2020 | 2020-12-31 | 10.59% | −4.90 pp |
| 2019 | 2019-12-31 | 15.50% | −6.71 pp |
| 2018 | 2018-12-31 | 22.21% | +10.66 pp |
| 2017 | 2017-12-31 | 11.54% | −5.92 pp |
| 2016 | 2016-12-31 | 17.46% | −0.19 pp |
| 2015 | 2015-12-31 | 17.65% | −0.54 pp |
| 2014 | 2014-12-31 | 18.18% | −2.26 pp |
| 2013 | 2013-12-31 | 20.45% | −1.72 pp |
| 2012 | 2012-12-31 | 22.17% | +3.29 pp |
| 2011 | 2011-12-31 | 18.88% | — |
Utah Medical Products quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.22% | −0.38 pp |
| Q1 2026 | 2026-03-31 | 2.17% | −0.42 pp |
| Q4 2025 | 2025-12-31 | 2.16% | −0.24 pp |
| Q3 2025 | 2025-09-30 | 2.23% | −0.64 pp |
| Q2 2025 | 2025-06-30 | 2.60% | −0.14 pp |
| Q1 2025 | 2025-03-31 | 2.59% | −0.50 pp |
| Q4 2024 | 2024-12-31 | 2.40% | −1.00 pp |
| Q3 2024 | 2024-09-30 | 2.87% | −0.34 pp |
| Q2 2024 | 2024-06-30 | 2.74% | −0.76 pp |
| Q1 2024 | 2024-03-31 | 3.09% | −0.54 pp |
| Q4 2023 | 2023-12-31 | 3.40% | −0.69 pp |
| Q3 2023 | 2023-09-30 | 3.21% | −0.76 pp |
| Q2 2023 | 2023-06-30 | 3.50% | −0.28 pp |
| Q1 2023 | 2023-03-31 | 3.63% | +0.36 pp |
| Q4 2022 | 2022-12-31 | 4.10% | +0.29 pp |
| Q3 2022 | 2022-09-30 | 3.97% | +0.10 pp |
| Q2 2022 | 2022-06-30 | 3.79% | +0.56 pp |
| Q1 2022 | 2022-03-31 | 3.27% | +0.36 pp |
| Q4 2021 | 2021-12-31 | 3.81% | +0.41 pp |
| Q3 2021 | 2021-09-30 | 3.87% | +0.84 pp |
| Q2 2021 | 2021-06-30 | 3.23% | +1.84 pp |
| Q1 2021 | 2021-03-31 | 2.91% | −0.30 pp |
| Q4 2020 | 2020-12-31 | 3.39% | −1.06 pp |
| Q3 2020 | 2020-09-30 | 3.03% | −0.89 pp |
| Q2 2020 | 2020-06-30 | 1.38% | −2.40 pp |
| Q1 2020 | 2020-03-31 | 3.21% | −0.25 pp |
| Q4 2019 | 2019-12-31 | 4.45% | +0.63 pp |
| Q3 2019 | 2019-09-30 | 3.92% | −3.93 pp |
| Q2 2019 | 2019-06-30 | 3.79% | −1.40 pp |
| Q1 2019 | 2019-03-31 | 3.47% | −1.62 pp |
| Q4 2018 | 2018-12-31 | 3.82% | +6.98 pp |
| Q3 2018 | 2018-09-30 | 7.85% | +3.28 pp |
| Q2 2018 | 2018-06-30 | 5.19% | +0.02 pp |
| Q1 2018 | 2018-03-31 | 5.09% | +0.10 pp |
| Q4 2017 | 2017-12-31 | −3.17% | −7.00 pp |
| Q3 2017 | 2017-09-30 | 4.57% | +0.49 pp |
| Q2 2017 | 2017-06-30 | 5.17% | +0.60 pp |
| Q1 2017 | 2017-03-31 | 4.99% | +0.43 pp |
| Q4 2016 | 2016-12-31 | 3.83% | −0.82 pp |
| Q3 2016 | 2016-09-30 | 4.08% | −0.38 pp |
| Q2 2016 | 2016-06-30 | 4.57% | +0.15 pp |
| Q1 2016 | 2016-03-31 | 4.55% | +0.40 pp |
| Q4 2015 | 2015-12-31 | 4.65% | −0.01 pp |
| Q3 2015 | 2015-09-30 | 4.46% | +0.09 pp |
| Q2 2015 | 2015-06-30 | 4.42% | −0.01 pp |
| Q1 2015 | 2015-03-31 | 4.15% | −0.25 pp |
| Q4 2014 | 2014-12-31 | 4.66% | −1.24 pp |
| Q3 2014 | 2014-09-30 | 4.37% | −0.32 pp |
| Q2 2014 | 2014-06-30 | 4.43% | −0.66 pp |
| Q1 2014 | 2014-03-31 | 4.41% | −0.97 pp |
| Q4 2013 | 2013-12-31 | 5.90% | +1.36 pp |
| Q3 2013 | 2013-09-30 | 4.69% | −1.09 pp |
| Q2 2013 | 2013-06-30 | 5.09% | −0.24 pp |
| Q1 2013 | 2013-03-31 | 5.38% | −1.16 pp |
| Q4 2012 | 2012-12-31 | 4.53% | −0.05 pp |
| Q3 2012 | 2012-09-30 | 5.77% | +0.21 pp |
| Q2 2012 | 2012-06-30 | 5.33% | +0.24 pp |
| Q1 2012 | 2012-03-31 | 6.54% | — |
| Q4 2011 | 2011-12-31 | 4.58% | — |
| Q3 2011 | 2011-09-30 | 5.57% | — |
| Q2 2011 | 2011-06-30 | 5.10% | — |
Utah Medical Products return on equity trends
Over the last five fiscal years, Utah Medical Products's return on equity decreased from 10.59% to 9.54%, a change of −1.05 percentage points. The latest reported quarter, Q2 2026, shows 2.22%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Utah Medical Products source filings ↗